Valye reports for unlimited access

OLAPLEX HOLDINGS, INC. is a foundational health and beauty company focused on delivering innovative haircare products inspired by professional hairstylists. Since its founding in 2014, OLAPLEX has developed patent-protected bond-building technology that repairs hair damage at the molecular level. The company offers a broad portfolio of approximately 30 products designed for use both in salons and at home, addressing various hair health needs including damage repair, hydration, and curl shaping. OLAPLEX sells its products globally in over 60 countries through three synergistic channels: professional distributors serving salons and licensed professionals, specialty retail stores and online retailers, and direct-to-consumer e-commerce platforms. The company emphasizes science-based innovation, brand engagement with professionals and consumers, and a flexible supply chain with manufacturing in the U.S. and Europe. OLAPLEX operates in the prestige haircare market segment, which is growing faster than the broader haircare market. The company is undertaking a business transformation plan to enhance its marketing, product development, and operational infrastructure. OLAPLEX holds a substantial intellectual property portfolio with patents extending into the 2030s and 2040s. The company faces competition from large multinational corporations and smaller independent brands. OLAPLEX reported a net loss for fiscal 2025 but maintains strong liquidity and cash reserves.

Ciena Corporation is a global technology company specializing in optical transport and switching systems, leveraging proprietary WaveLogic coherent modem technology to serve long-haul, submarine, metro, regional networks, and data center interconnects. The company is expanding its market presence in data center interconnect and metro/edge networking through advanced hardware and software solutions, including the integration of IP routing with coherent optical technologies. Ciena offers platform software for network automation and lifecycle management, alongside a broad portfolio of services such as advisory, implementation, and maintenance. Its customer base includes cloud providers, communications service providers, cable operators, governments, and enterprises, with sales distributed across Americas, EMEA, and APAC regions. The company maintains a global partner program to extend market reach and reduce operational risks. Financially, Ciena reported approximately $1.43 billion in revenue and $150 million in net income for Q1 2026, supported by a strong liquidity position.

Research Frontiers Inc. develops and licenses SPD-Smart light-control technology, which is used in various applications including smart windows, skylights, and automotive glass. The company operates through licensing agreements with over 40 licensees worldwide, who manufacture and market products incorporating SPD technology. The company recognizes revenue primarily from license fees and royalties based on licensees' sales performance. The automotive and architectural sectors are key markets for the company. Research Frontiers does not engage in direct manufacturing but supports market development to aid licensees. The company operates as a single segment and derives most of its revenue from international sources. Financially, the company has experienced recurring net losses and maintains a strong liquidity position with cash, short-term investments, and working capital sufficient to support ongoing operations. The company faces operational risks related to licensee performance, supply chain dependencies, and competitive pressures.

Quest Water Global, Inc. is an innovative water technology company that develops and sells sustainable water purification and distribution systems targeting water-scarce regions globally. Its primary products are the AQUAtap™ Community Water Purification & Distribution system, a solar-powered, autonomous unit capable of purifying up to 100,000 liters of water daily, and the WEPS™ system, which extracts potable water from atmospheric humidity. The company focuses on underserved rural and peri-urban communities in North America, Latin America, the Caribbean, and Africa, with significant operations in the Democratic Republic of the Congo, Angola, and South Africa. Quest Water employs a proprietary Build-Own-Operate community business model that partners with governments, NGOs, and local organizations to establish self-serve water vending systems. The company’s technology is designed to be environmentally sustainable, chemical-free, and adaptable to various water sources. Quest Water’s operations include product design, manufacturing, and sales through corporate divisions and global distributors. The company has a small workforce supplemented by contractors and has formed strategic partnerships to expand its reach and impact.

Intrepid Potash, Inc. produces essential mineral products including potash, Trio® fertilizer, and water-related products for agriculture, animal feed, and oil and gas industries. It is the sole U.S. producer of muriate of potash, operating three solar evaporation solution mines in New Mexico and Utah, and a conventional underground mine for Trio® production. The company also manages oilfield solutions through its Intrepid South property, offering water, brine, and related services in the Permian Basin. Its product portfolio includes byproducts such as salt, magnesium chloride, and brines. Intrepid's business model leverages its geographic location for transportation advantages and lower tax burdens, focusing on maximizing gross margins and optimizing production. The company pursues diversification through lithium extraction development and expanding oilfield offerings. It faces market and operational risks typical of the mining and fertilizer industries.

Ardagh Metal Packaging S.A. operates internationally, supplying metal cans primarily for the beverage industry. Its business model depends on managing raw material and energy cost volatility through contractual pass-throughs and forward purchasing. The company’s revenue and profitability are influenced by global economic conditions, consumer demand, production capacity, and currency fluctuations. It reported increasing revenues and improved net income in 2025 compared to prior years. The company maintains liquidity through cash balances and committed credit facilities, supporting operational and capital needs. Governance is structured with a nine-member Board and multiple committees, including audit and sustainability. Risk management encompasses financial, operational, and cybersecurity risks, with established policies and external oversight.

L.B. Foster Company, founded in 1902 and headquartered in Pittsburgh, PA, provides engineered products and services that support infrastructure globally. It operates two main segments: Rail, Technologies, and Services, which includes manufacturing and distribution of rail products, friction management, and technology solutions; and Infrastructure Solutions, which offers precast concrete products, steel bridge components, and pipeline protective coatings. The Rail segment serves freight and passenger railroads worldwide, while Infrastructure Solutions primarily serves North American civil and energy infrastructure markets. The company maintains a global sales presence with approximately 11% of sales outside the US in 2025. It employs over 1,190 people and emphasizes safety, environmental responsibility, and ethical business practices. The company faces competitive markets with multiple competitors in each product line and manages risks related to raw material sourcing, international operations, and regulatory compliance [S1].

Solitario Resources Corp. is a smaller reporting company incorporated in Colorado in 1984, engaged in mineral exploration since 1993. Its business model centers on acquiring exploration mineral properties, advancing them through exploration and joint ventures, and potentially selling, developing, or creating royalties on these properties. The company has never developed a property itself. Its core assets include interests in zinc and precious metal projects in Peru, Alaska, South Dakota, and Colorado. Exploration is conducted both independently and through joint ventures with partners such as Nexa Resources Ltd. and Teck American Inc. The company funds its operations through equity issuances, sales of marketable securities, and joint venture payments. It maintains a small workforce supplemented by consultants and contractors. The company is subject to risks inherent in mineral exploration, including the possibility that exploration expenditures may not be recovered if properties cannot be sold or developed. Commodity price fluctuations and geopolitical factors also impact its operations and asset values. [S1]

Park-Ohio Holdings Corp is a diversified industrial company operating through three segments: Supply Technologies, Assembly Components, and Engineered Products. The Supply Technologies segment provides total supply management solutions and manufactures engineered specialty fasteners. Assembly Components designs and manufactures fuel rails, pipes, and flexible assemblies for fuel transport in vehicles. Engineered Products includes niche manufacturing businesses producing induction heating and melting systems, pipe threading systems, forged and machined products, and related services. The company sells products globally, with significant sales in the U.S., Europe, Asia, Mexico, and Canada. Revenue recognition varies by segment and contract type, including point-in-time and over-time methods. The company completed the sale of its Aluminum Products business in late 2023, classified as discontinued operations. Park-Ohio finances operations through a combination of cash flow, credit facilities, and debt securities, including senior secured notes. The company maintains a share repurchase program and pays quarterly dividends. It faces typical industrial sector risks including market demand variability, supply chain issues, and legal contingencies such as asbestos-related claims [S1].

Uwharrie Capital Corp operates as a financial services company with subsidiaries including a bank and investment advisory services. The company’s business involves managing loans, investment securities, and other financial assets. It reports detailed financial data in SEC filings, including cash holdings, earnings per share, and net income. The company pays dividends on preferred stock classified as noncontrolling interest. No material legal proceedings were reported as of the end of 2025. Recent quarterly and annual financial results show profitability and growth in net income.

Carter Bankshares, Inc. is a bank holding company with operations concentrated in Virginia and North Carolina. It provides banking services primarily through its subsidiary, Carter Bank & Trust. The company operates under extensive federal and state regulatory frameworks that govern capital adequacy, liquidity, lending practices, privacy, anti-money laundering, and cybersecurity. It maintains prudent underwriting standards, particularly in commercial real estate lending, and manages risk through board oversight and strategic planning. The company relies on dividends from its bank subsidiary for revenue and maintains multiple liquidity sources to support its operations. Competition is significant from larger banks and non-bank financial service providers. The company faces operational risks including fraud and reliance on third-party providers, and it actively monitors regulatory developments affecting its business.

Stratasys Ltd. operates as a global provider of polymer-based 3D printing solutions, serving a broad range of industries including aerospace, automotive, healthcare, and consumer products. The company’s product portfolio includes 3D printers, materials, software, expert services, and on-demand parts production. Stratasys focuses on manufacturing as its primary market, leveraging its extensive patent portfolio and global go-to-market infrastructure. The company operates primarily through offices in Israel, the United States, Germany, Hong Kong, and Japan. It generates revenue from sales of 3D printing systems, consumables, services, and additive manufacturing solutions. Stratasys has undertaken strategic restructuring to streamline operations and enhance profitability, including workforce reductions and focusing on high-growth product lines. The company’s financials show a decline in revenue over recent years and ongoing net losses, with a solid liquidity position as of the end of 2025.

The Toro Company is a Delaware-based corporation engaged in manufacturing and selling equipment solutions, including lawn and turf maintenance products and industrial equipment. The company expanded its industrial equipment segment through the acquisition of Tornado Infrastructure Equipment Ltd., a manufacturer of vacuum trucks and equipment for underground construction and energy markets. TTC finances its operations through a combination of cash, credit facilities, and debt issuance, including senior notes. The company maintains a stock repurchase program authorized to buy back shares in the open market. Recent SEC filings provide detailed financial data and risk disclosures, supporting transparency in its business operations.

Global Crossing Airlines Group Inc. is a U.S.-based Part 121 domestic flag and supplemental airline operating primarily Airbus A320 family aircraft. The company’s business model includes providing aircraft, crew, maintenance, and insurance (ACMI) services under wet lease contracts to other airlines, and offering full-service passenger charter flights on an all-inclusive fee basis. Operations span the United States, Europe, Canada, the Caribbean, and Central and South America. The company’s fleet includes sixteen passenger A320-200 aircraft and four cargo A321F aircraft as of December 31, 2025, with plans to increase the passenger fleet to twenty-one aircraft within the next year. The main operational base is Miami International Airport, with additional crew and operational bases in Texas, Louisiana, and Arizona. The company employs approximately 661 full-time employees. Revenue is generated primarily from ACMI contracts and charter services, with one customer accounting for 50% of revenue in 2025. The company operates in a single reportable segment and is subject to comprehensive federal aviation and consumer regulations.

OFG Bancorp is a financial services company incorporated in the Commonwealth of Puerto Rico, publicly traded on the NYSE under the ticker OFG. The company files regular SEC reports including annual 10-K/A filings and quarterly 10-Qs, providing detailed financial disclosures. As of the end of 2025, OFG Bancorp reported strong profitability metrics and significant liquidity. The company has attracted market and analyst attention for its dividend yield and insider buying activity, reflecting active engagement with shareholders and the investment community.

Nokia Corporation operates as a global leader in connectivity technologies, focusing on fixed, mobile, and transport networks to support the AI era. The company has a long history dating back to 1896 and is headquartered in Finland. Its business model centers on advancing network infrastructure and software solutions to enable secure and efficient connectivity worldwide. Nokia's operations are segmented into Mobile Infrastructure, Network Infrastructure, and Portfolio Businesses, each contributing to its technology and service offerings. The company invests significantly in research and development to maintain technological leadership and innovation. Nokia's financial reporting follows IFRS standards, with consolidated statements published annually and quarterly. Institutional investors hold notable stakes, reflecting market interest and governance oversight.

Ranpak Holdings Corp. specializes in environmentally sustainable protective packaging solutions and automation for e-commerce and industrial supply chains. Founded in 1972, the company offers 100% recyclable, renewable, and biodegradable paper-based packaging systems, including Void-Fill, Cushioning, and Wrapping products. Ranpak's business model centers on selling proprietary PPS systems coupled with exclusive high-margin paper consumables, generating recurring revenue. Automation products, including machine vision and robotics-enhanced solutions, complement the PPS offerings and address efficiency and cost reduction in end-of-line packaging. The company distributes primarily through a global network of over 250 distributors and direct sales to select large end-users. Ranpak operates two main geographic segments: North America and Europe/Asia, with a growing presence in Asia supported by a Malaysia facility. The company emphasizes innovation, sustainability, and geographic expansion as strategic priorities.

National Research Corporation, doing business as NRC Health, provides performance measurement and improvement services primarily to healthcare providers and payers. The company’s revenue is largely derived from renewable service contracts with healthcare customers, with a concentration in a limited number of key clients. NRC Health competes in a highly competitive market against firms such as Press Ganey and Qualtrics, as well as internal departments within healthcare organizations. The company outsources certain survey data collection and outreach operations to third-party vendors critical to its service delivery. NRC Health’s business is influenced by healthcare industry regulations, economic conditions, and consolidation trends. The company’s financial position as of December 31, 2025, shows limited liquidity with a current ratio of 0.55 and cash ratio of 0.11. Earnings per share were reported at $50 for 2025, with historical revenue and net income figures available for 2018. Recent news highlights fluctuations in earnings, client attrition, rising interest costs, and management changes.

Evaxion A/S is a clinical-stage biotechnology company focused on developing vaccines using its proprietary AI-Immunology platform. The company targets cancer, bacterial, and viral diseases through AI-designed immunotherapies. Revenue is generated mainly from licensing and collaborative research agreements, notably with Merck & Co. The company invests significantly in research and development, with expenses primarily related to internal and external costs for product candidate development and technology platform maintenance. General and administrative expenses cover corporate functions and related overhead. Evaxion maintains a strong liquidity position supported by recent equity financing and debt-to-equity conversions. The company has ongoing clinical trials and continues to expand its vaccine pipeline, including candidates for cancer and Group A Streptococcus infections. Leadership changes occurred in 2025, with an interim CEO and new CFO appointed. The company operates primarily in Denmark with long-term leases for office and laboratory facilities.

Liquidia Corp develops and commercializes therapies for pulmonary arterial hypertension and related pulmonary vascular diseases. Its lead commercial product, YUTREPIA, is an inhaled dry powder formulation of treprostinil using proprietary PRINT particle engineering technology, approved by the FDA in May 2025. The company also markets generic treprostinil injection in partnership with Sandoz under a profit-sharing promotion agreement. Liquidia operates manufacturing and R&D facilities in Morrisville, North Carolina, with plans to expand capacity through a new leased facility. The company is advancing clinical development of L606, a liposomal treprostinil formulation, and plans additional clinical studies for other pulmonary hypertension indications. Commercial efforts target specialized healthcare providers and centers of excellence in the US. The company has experienced recurring operating losses but maintains liquidity to support ongoing operations and development activities.

MYERS INDUSTRIES INC operates primarily in manufacturing and distribution, with key segments including Material Handling and Distribution. The company acquired Signature Systems in 2024, expanding its composite matting product offerings for industrial and event applications. Revenue is recognized when control of products transfers to customers, generally within 90 days, with no significant long-term contracts. The company manages variable consideration such as rebates and discounts and allows product returns in the ordinary course of business. Financially, as of the end of 2025, the company maintains a current ratio of 1.67 and reported net income of $34.93 million for the fiscal year. The company uses interest rate swaps to hedge floating rate debt and has a significant amount of long-term debt. Recent strategic initiatives include a review of the tire supply business and leadership appointments.

flyExclusive, Inc. operates in the aviation sector, providing fractional ownership and related services for aircraft. The company is headquartered in Kinston, North Carolina, and is publicly traded on the NYSE American under the ticker FLYX. flyExclusive completed a merger and reorganization involving Jet.AI and its subsidiaries, which is part of its corporate structure. The company finances its aircraft acquisitions and operations partly through secured debt instruments, including a Senior Secured Note with amendments extending maturity and adjusting interest rates. flyExclusive reported a net loss for the fiscal year ended December 31, 2025, and its liquidity ratios indicate a current ratio of 0.28 and a cash ratio of 0.11, suggesting limited short-term liquidity. The company is involved in ongoing litigation with Wheels Up Partners LLC concerning a terminated Fleet Guaranteed Revenue Program Agreement, with multiple legal proceedings ongoing. Operationally, flyExclusive announced a record Thanksgiving holiday weekend, indicating active customer engagement and utilization of its services.

Linear Minerals Corp is a junior resource company incorporated in British Columbia, Canada, engaged in the acquisition and exploration of mineral properties, with a focus on lithium and rare earth elements. The company’s main property is the Augustus Lithium Project in Quebec, comprising over 46,000 hectares of mining claims. Exploration activities include prospecting, mapping, sampling, and diamond drilling, with multiple drill programs reporting lithium oxide mineralization. The company has a joint venture agreement with Infini Resources Pty Ltd for part of the Augustus Property. Linear Minerals has no producing mines and relies on equity financing to fund its exploration and administrative expenses. The company’s shares trade on the Canadian Securities Exchange, OTCQB, and Frankfurt markets. Its executive office is located in Vancouver, British Columbia.

CorMedix Inc. operates as a biopharmaceutical company with a focus on therapeutic products addressing life-threatening conditions. Its primary commercial product, DefenCath®, is an FDA-approved antimicrobial catheter lock solution indicated to reduce catheter-related bloodstream infections in adult hemodialysis patients. Launched in 2024, DefenCath is the largest contributor to the company's net sales and is supported by multi-year supply agreements covering approximately 60% of U.S. outpatient dialysis centers. In August 2025, CorMedix acquired Melinta Therapeutics, expanding its portfolio with six marketed infectious disease products and one cardiovascular product, enhancing its multi-channel commercial strategy targeting hospital and clinic settings. The company pursues expanded indications for DefenCath and other products, including ongoing Phase 3 clinical trials for new uses. Manufacturing is outsourced to FDA-approved contract manufacturers primarily in Europe and the U.S., with ongoing efforts to onshore production and reduce costs. CorMedix holds a government contract with BARDA supporting pediatric and biothreat pathogen development programs. The company reported profitability in 2025 with significant revenue growth and maintains liquidity with a current ratio above 2.0. Risks include integration challenges, reimbursement transitions, supply chain tariffs, clinical trial uncertainties, and customer concentration.

Acorn Energy, Inc. is a Delaware holding company focused on technology-driven solutions for energy infrastructure asset management, primarily through its OmniMetrix subsidiary. OmniMetrix operates two main segments: Power Generation (PG) and Cathodic Protection (CP). The PG segment offers wireless remote monitoring and control systems and IoT applications for commercial, industrial, and residential power generation equipment. In 2025, OmniMetrix launched the Omni family of products built on the proprietary OCOM communications platform, replacing legacy TrueGuard products and enhancing connectivity and ease of installation. The CP segment provides remote monitoring and control products for cathodic protection systems on gas pipelines, including the RADex product launched in 2025 that adds cathodic protection measurement capabilities. OmniMetrix's products serve critical infrastructure across various sectors including telecommunications, manufacturing, medical, data centers, retail, transportation, energy distribution, and government. The company emphasizes prognostic solutions to prevent equipment failures and has shifted focus toward commercial and industrial markets. Acorn Energy reported $11.478 million in revenues and $2.51 million net income for 2025, with a strong gross margin of 77%. The company entered a strategic partnership in 2026 to expand its infrastructure asset management technology offerings in North America.

Rand Capital Corporation operates as a regulated business development company (BDC) and elects to be treated as a regulated investment company (RIC) for U.S. federal tax purposes. The company focuses on generating current income primarily through investments in higher yielding debt instruments in privately held, lower middle market companies with revenues exceeding $10 million and EBITDA above $1.5 million. Rand typically makes minority investments ranging from $2 million to $4 million per portfolio company and seeks board observation or board seats to monitor its investments. The company is externally managed and advised by RCM, which oversees the investment process including sourcing, due diligence, investment decisions, and portfolio management. Rand competes with other venture capital firms, BDCs, and private equity funds, leveraging RCM's referral network and investment expertise. The company declared quarterly dividends in 2025 and maintains a portfolio diversified in compliance with SEC and IRS regulations. Rand's shares trade on the Nasdaq Capital Market under the symbol 'RAND'.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing drug candidates targeting liver and viral diseases. The company’s pipeline includes a chronic hepatitis B drug candidate, pevifoscorvir sodium, currently in Phase 2 clinical trials, alongside other programs in MASH and coronavirus. Aligos funds its operations primarily through equity offerings, collaborations, and licensing agreements. The company recognizes revenue mainly from license and collaboration agreements, with payments often contingent on development milestones and royalties. As of December 31, 2025, Aligos held $77.8 million in cash and short-term investments and reported a net loss of $24.2 million for the fiscal year. Operating expenses are dominated by research and development activities and general administrative costs. The company’s cash resources are sufficient to fund operations into the third quarter of 2026, requiring additional capital to sustain ongoing development and potential commercialization efforts. Aligos operates under U.S. GAAP accounting standards and discloses risks related to its limited operating history, financial position, and need for additional capital [S1].

Okta Inc is a technology company specializing in cloud-based identity and access management solutions. Its core offerings are the Okta Platform and Auth0 Platform, which enable organizations to securely connect users—employees, contractors, partners, customers, and increasingly AI agents—to applications and services across cloud, mobile, web, and on-premises environments. The company emphasizes technological neutrality, supporting integration with a wide range of applications and infrastructure. Okta's platforms provide adaptive access, multi-factor authentication, lifecycle management, identity governance, and security posture management. The company is innovating to address emerging identity challenges related to AI agents and non-human identities, offering early access products to govern these new identity types. Okta serves a diverse customer base of over 20,000 organizations worldwide and operates primarily on a SaaS subscription model, selling through direct and indirect channels. Its growth strategy focuses on deepening customer relationships, expanding large enterprise accounts, leveraging a broad partner ecosystem, and growing its international presence. Okta maintains multiple security and privacy certifications and commits to high service levels. Financially, as of January 31, 2026, Okta reported profitability with net income of $235 million and maintains solid liquidity metrics. The company faces risks from intense competition, economic conditions affecting customer spending, cybersecurity threats, and operational challenges related to growth and restructuring [S1][S2].

Bioventus Inc. develops and markets medical devices and therapies primarily focused on active healing in orthopedic and surgical fields. Its product portfolio includes hyaluronic acid-based viscosupplementation therapies for osteoarthritis pain, surgical solutions such as bone graft substitutes and ultrasonic bone cutting systems, and restorative therapies including minimally invasive fracture treatments. The company sells products mainly through a direct sales force to healthcare providers and distributors in the U.S. and international markets. In late 2024, Bioventus divested its Advanced Rehabilitation Business, using proceeds to reduce debt. The company has recently expanded its portfolio with FDA-cleared Peripheral Nerve Stimulation devices for chronic pain management, initiating commercial launches in late 2025 and early 2026. Bioventus reports revenue net of rebates and allowances, with reserves based on historical and market data. The company maintains a board with extensive healthcare and financial expertise to guide strategy and governance.

Silence Therapeutics plc is a biotechnology company incorporated in England and Wales, with its principal executive offices located in London. The company’s securities trade on The Nasdaq Stock Market as American Depositary Shares under the ticker SLN. Financial disclosures indicate the company operates with significant net losses and negative earnings per share, reflecting ongoing investment or development phases typical in biotech sectors. The company maintains strong liquidity with a high current ratio and cash ratio as of the end of 2025. Recent operational updates include a substantial revenue decrease reported in mid-2025 and a strategic transition to U.S. issuer status in 2026. Cybersecurity risk is a recognized concern, with governance structures in place to manage related risks.

Distribution Solutions Group, Inc. (DSG) is a diversified distributor operating through four reportable segments: Lawson, TestEquity, Gexpro Services, and Canada Branch Division. Lawson focuses on specialty products and services for the industrial, commercial, institutional, and government MRO marketplace in North America. TestEquity distributes test and measurement equipment and related industrial and electronic supplies, serving sectors such as aerospace, defense, and electronics manufacturing. Gexpro Services provides global supply chain solutions including production line management and aftermarket services. The Canada Branch Division serves the Canadian MRO market through its Bolt and Source Atlantic subsidiaries. The company’s revenue is generated through product sales, services, and vendor managed inventory programs, with contracts typically short cycle in nature. DSG’s business is influenced by manufacturing sector conditions, supply chain dynamics, and strategic acquisitions. The company amended its senior secured credit facility in December 2025, increasing borrowing capacity and extending maturity. It also increased its stock repurchase program authorization in November 2025. Liquidity metrics as of December 31, 2025 indicate a strong current ratio of 2.56 and cash ratio of 0.21. [S1]

Kura Oncology, Inc. is a biopharmaceutical company committed to developing precision medicines targeting cancer signaling pathways. Since its founding in 2014, it has evolved into a fully integrated commercial-stage company with a diversified pipeline. Its lead product, KOMZIFTI (ziftomenib), is an FDA-approved menin inhibitor for relapsed or refractory AML with NPM1 mutation, launched commercially in the U.S. in late 2025. The company is advancing multiple clinical trials for ziftomenib in AML, including combinations with standard therapies and in various patient populations. Additionally, Kura is developing next-generation menin inhibitors for diabetes and solid tumors, as well as farnesyl transferase inhibitors for solid tumors and head and neck cancers. The company’s financial position as of the end of 2025 reflects significant investment in R&D and commercialization, supported by substantial cash reserves and collaboration revenues.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapeutics based on proprietary antibody technologies. The company’s scientific focus is on the interplay between angiogenesis, immune system activation, and tumor growth. Its pipeline includes four clinical-stage product candidates: tovecimig (a bispecific antibody targeting DLL4 and VEGF-A), CTX-471 (a CD137 agonist antibody), CTX-8371 (a bispecific antibody targeting PD-1 and PD-L1), and CTX-10726 (a bispecific antibody targeting PD-1 and VEGF-A). Tovecimig is in a randomized Phase 2/3 trial for biliary tract cancer, having met its primary endpoint with a significant improvement in overall response rate. The company plans to expand tovecimig’s development into other solid tumors and advance its other candidates through clinical trials. Compass Therapeutics holds worldwide rights to its candidates except for limited territories for tovecimig and relies on third-party manufacturers. The company reported a net loss of $66.5 million for the fiscal year ended December 31, 2025, with strong liquidity and cash resources to fund operations into 2028. The company’s strategy includes clinical development, potential combination therapies, and selective strategic partnerships [S1].

MediWound Ltd. is an Israeli biopharmaceutical company founded in 2000, focused on developing and commercializing products for the treatment of burns and other wounds. Its flagship product, Nexobrid, is a topical enzymatic debridement treatment for burn injuries, commercialized globally with a key partnership with Vericel in North America. The company also develops EscharEx for diabetic foot ulcers, supported by European Innovation Council grants. MediWound’s business model includes product sales, license agreements, royalties, and government contracts, notably with BARDA and the U.S. Department of War through MTEC, which provide significant funding for research, development, and procurement. The company has expanded its manufacturing capacity with a new GMP-compliant facility commissioned in 2025. Revenues are primarily generated in the U.S. market, with major customers including government agencies and Vericel. MediWound reported a net loss in 2025, reflecting ongoing investment in R&D and commercialization.

Tango Therapeutics, Inc. focuses on discovering and developing precision oncology therapies targeting genetic alterations in cancer cells. Its pipeline includes PRMT5 inhibitors vopimetostat (TNG462) for non-CNS cancers and TNG456 for CNS cancers, with ongoing Phase 1/2 trials showing promising clinical activity and safety. The company is also developing TNG961, a molecular glue candidate targeting HBS1L, and TNG260, a CoREST inhibitor with encouraging data in NSCLC. Tango funds operations primarily through equity offerings and collaborations, notably with Gilead Sciences. As of December 31, 2025, it held $343.1 million in cash and marketable securities and reported $62.4 million in revenue with a net loss of $101.6 million for the year. The company trades on Nasdaq under TNGX and maintains a corporate headquarters in Boston, Massachusetts.

CPI Card Group Inc. is a provider of payment card solutions and related services primarily in the U.S. market. Its product portfolio includes debit, credit, prepaid, and instant issuance cards, along with personalization and fulfillment services. The company operates through segments including Debit and Credit, Prepaid Debit, and Other corporate expenses. It serves a concentrated customer base, with significant revenue derived from a few large customers. The company recognizes product revenue at point-in-time and services revenue over time as services are performed. CPI Card Group faces a competitive landscape with larger global competitors and must continuously innovate to maintain market share. The company has experienced supply chain challenges and inflationary pressures impacting production and delivery. It completed the acquisition of Arroweye Solutions, Inc. in 2025, integrating its operations. Financially, the company reported net income of $14.95 million for fiscal 2025 and maintains liquidity with a current ratio of 2.44 as of year-end 2025.